Pharm-Olam México

Pharm-Olam has conducted studies in México since 2003 and has an office in the capital of México City. Data from our Mexico studies later supported US NDA and EMA approval in gram positive infections. Pharm-Olam is registered with the national MoH (COFEPRIS) and can submit regulatory in our name and serve as an importer/exporter for IMP. We are experienced with Product Registration in México.

There are 8 certified College of American Pathologists labs in México.

México City as a metro area population of 18.6 million to enroll patients for clinical trials. México has high incidence of particular disorders including, type 2 diabetes, metabolic syndrome, gallbladder cancer, and osteoporosis.

Pharm-Olam offers comprehensive services and functional outsourcing for Phase I to IV clinical research studies in México, including monitoring, regulatory, pharmacovigilance, data management, project management, and biostatistics.

For more information on conducting clinical trials with Pharm-Olam in México, please Contact Us.

Office Location: México City

México Demographics

Population: 111.2 million (77% urbanized)
Median Age: 25.6 years
Language: Spanish
Market: In 2010 México had the 14th largest pharmaceutical market in the world.

Regulatory Authorities

COFEPRIS - Ministry of Health (in Spanish)

Clinical Trials in México

clinicaltrials.gov Active Studies

Argentina (Buenos Aires), Belarus (Minsk), Belgium (Brussels), Brazil (São Paulo), Bulgaria (Sofia), Canada (Toronto), Croatia (Zagreb), Czech Rep. (Prague), Georgia (Tbilisi), Germany (Munich), Hungary (Budapest), India (Bangalore), Italy (Milan), Kazakhstan (Almaty), Mexico (Mexico City), Poland (Warsaw), Romania (Bucharest), Russia (Moscow, St. Petersburg, Novosibirsk), Serbia (Belgrade), Spain (Madrid), South Africa (Johannesburg), Ukraine (Kiev), United Kingdom (London), United States (Houston, Princeton, Research Triangle Park)